title: Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.
abstract: A hepatitis B virus (HBV) vaccine has been developed using a new adjuvant and HBV surface antigens produced from a CHO cell line. The purified HBV surface antigens are composed of L protein, M protein, and S protein in a mixture of 20- and 40-nm-diameter particles and filamentous forms. This HBV surface antigen, formulated with L-pampo, a proprietary adjuvant, induced 10 times more antibody than the same antigen with alum and was capable of inducing strong immune responses in three different HBV transgenic mice. In spite of the presence of a large amount of HBV antigen in the blood, no antibody against HBV surface antigen was normally detected in these transgenic mice. After immunization, the HBV antigen was also cleared from the blood.
authors.affiliation: R&D Center, CHA Vaccine Institute, Seongnam-si, Gyeonggi, South Korea.
authors.forename: Jung Sun
authors.initials: JS
authors.lastname: Yum
authors.forename: Byung Cheol
authors.initials: BC
authors.lastname: Ahn
authors.forename: Hyun Jin
authors.initials: HJ
authors.lastname: Jo
authors.forename: Dong Yeon
authors.initials: DY
authors.lastname: Kim
authors.forename: Ki Hyun
authors.initials: KH
authors.lastname: Kim
authors.forename: Hyo Sun
authors.initials: HS
authors.lastname: Kim
authors.forename: Young Chul
authors.initials: YC
authors.lastname: Sung
authors.forename: Jaeseung
authors.initials: J
authors.lastname: Yoon
authors.forename: John
authors.initials: J
authors.lastname: Morrey
authors.forename: Hong Mo
authors.initials: HM
authors.lastname: Moon
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016466:CHO Cells; D006224:Cricetinae; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology* / Q000378:metabolism; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011498:Protein Precursors / Q000276:immunology* / Q000378:metabolism; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011498:Protein Precursors; D014759:Viral Envelope Proteins; C050806:presurface protein 1, hepatitis B surface antigen; D000410:Alanine Transaminase